Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

Completed

• Conditions: Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Pheochromocytoma; Hemangioblastoma; Renal Cell Carcinoma
• Interventions: Other: 89Zr bevacizumab PET scan

• Registration Number: NCT00970970
• Lead Sponsor: University Medical Center Groningen

Brief Summary

Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors. The VHL protein is not functional in the different disease associated lesions which results in production of high amounts of vascular endothelial growth factor (VEGF). Currently there are no clinical, radiographic or molecular markers that can predict the natural history of a given lesion. With 89Zr-bevacizumab positron emission tomography (PET) scanning, VEGF can be visualized and quantified.

The investigators hypothesize that 89Zr-bevacizumab PET imaging is a useful tool to predict the behaviour of disease associated lesions in patients with VHLD.

Adult patients with VHLD who have had routine magnetic resonance imaging (MRI) scans of central nervous system (CNS) and abdomen will undergo a 89Zr-bevacizumab PET scan. MRI will be repeated within 12 months.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-09
• Study First Submitted: 2009-09-02
• Study First Submitted QC: 2009-09-02
• Study First Posted: 2009-09-03
• Primary Completion: 2012-11
• Study Completion: 2012-11
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-03
• Last Update Posted: 2024-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• clinically or genetically proven VHLD
• at least 1 measurable, VHL associated lesion in the CNS
• routine MRI of the CNS ≤ 6 weeks before inclusion
• routine CT or MRI of upper abdomen ≤ 3 months before inclusion or planned ≤ 3 months after 89Zr-bevacizumab PET scan
• age ≥ 18 years
• written informed consent must be given according to good clinical practice (GCP), and local regulations

Exclusion Criteria

• pregnancy
• any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol, those conditions should be discussed with the patient before registration in the trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Von Hippel Lindau	89Zr bevacizumab PET scan	Adult patients with Von Hippel-Lindau disease

Primary Outcome Measures

Name	Time	Method
Detection rate of VHL associated lesions with 89Zr-bevacizumab PET scans in patients with VHLD	An 89Zr-bevacizumab PET scan will be performed within 6 weeks after routine MRI CNS investigation, MRI will be repeated within 12 months.

Secondary Outcome Measures

Name	Time	Method
Progressive lesions within 12 months, defined as new lesions or lesions that show an increase in size of at least 5% of the longest diameter on MRI, or lesions that become symptomatic	The baseline MRI scan will be compared with a follow-up MRI scan within 12 months

Trial Locations

Locations (1)

University Medical Center Groningen; 🇳🇱 Groningen, Netherlands